White paper

The Inflation Reduction Act (IRA) and its implications for intellectual property incentives to develop drugs for select populations

The pharmaceutical industry has long thrived on strong intellectual property (IP) incentives, driving groundbreaking drug development that extends life expectancy, cures diseases, and fuels the global economy. However, the Inflation Reduction Act (IRA) introduces new Medicare drug price negotiation provisions that could disrupt this delicate balance.  
Washington Capital Building
Washington Capital Building
This white paper examines the historical role of IP laws in fostering innovation for critical populations, including those with rare diseases, pediatric patients, and those relying on generic medicines. It also explores how IRA’s pricing policies may deter investment in life-saving research and hinder initiatives like the Cancer Moonshot and pandemic preparedness. Finally, the paper offers insights into potential legislative adjustments that could sustain innovation while preserving the government’s role in drug pricing negotiations.  

Download the white paper to understand the future of pharmaceutical innovation in the wake of IRA.
Washington Capital Building

Related resources

Webinar

Thinking ahead: How integrated development plans improve product success
Learn more

Article

Insights from Pharma 2025: Patient empowerment through the European Health Data Space (EHDS)
Learn more

Article

Insights from Pharma 2025: Unlocking innovation: New models and next-gen tech for success
Learn more

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.